Saturday, September 23, 2023
Saturday, September 23, 2023

Deborah Heart and Lung Center Introduces the Ivenix Infusion System to the Hospital

Deborah Heart and Lung Center announces its successful hospital-wide go live with Ivenix, a modern smart infusion pump system.

“Though everyone is familiar with IV pump delivery systems used to administer medications during a patient’s hospital stay, improvements in technology have allowed us to do it in a controlled and measured way,” said Rita Zenna, RN, Deborah’s Vice President for Patient Care Services. “This is why we replaced our existing pumps with Ivenix, a state-of-the-art infusion system capable of measuring and controlling medication delivery.”

“Our staff is thrilled with how easy the new pumps are to work with and the enhanced capabilities that are offered,” added Sue Campano, Deborah’s Vice President for Support Services. “Our nurses collaborated extensively when evaluating our choices and ultimately selected Ivenix, a solution they believed would best meet their ability to care for patients.”

“We are enthusiastic about the opportunity to partner with Deborah Heart and Lung Center and bring this innovative infusion system to more clinicians and patients,” said Susan Niemeier, Chief Nursing Officer of Ivenix. “Advancing medication safety and clinical outcomes is critical for a hospital, and we’re honored to support the Deborah Heart’s efforts to protect patient health.”

The Ivenix Infusion System includes a large-volume infusion pump, portfolio of administration sets, and infusion management software with unique capabilities new to the infusion therapy market. Its adaptive fluid delivery reduces flow and accuracy variability to help improve patient safety. Its patient-centered design benefits patients because clinicians spend less time troubleshooting pumps or resolving nuisance alarms, which simplifies infusion delivery for those providing bedside care. Additionally, the Ivenix System can seamlessly integrate with Deborah Heart’s electronic medical record and other hospital information systems, further reducing the possibility of patient medication errors.

“We are excited about how the system is designed to prevent medication errors, reduce nuisance alarms and other common interruptions,” said Zenna. “This will have a significant impact on our ability to provide high-quality care and ensure our patients get the rest needed after surgery.” She added, “We continue to invest in smart technology, and this was a natural next step for us. Our clinical teams are pleased with how smoothly the system was rolled out across the entire hospital.”

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

FDA OK’s ensoETM for Use in Cardiac Ablations to Reduce Risk of Esophageal Injury

Published studies that have examined the use of ensoETM for this purpose include the pilot eCOOL-AF study, the IMPACT study and a large multi-center analysis of over 25,000 patients (in press at the Journal of the American College of Cardiology: Clinical Electrophysiology). These studies have found up to an 83 percent reduction in esophageal injuries, and a significant reduction in risk of atrioesophageal fistula (AEF), one of the most dreaded complications of ablation procedures. Receives FDA Clearance and Breakthrough Device Designation has also received FDA Breakthrough Device Designation for its obstructive hydrocephalus software tool. This is the first radiology triage device to be granted Breakthrough status since the inception of the FDA Breakthrough Devices Program.

By using this website you agree to accept Medical Device News Magazine Privacy Policy